A Novel CD34-Specific T Cell Engager Efficiently Depletes Acute Myeloid Leukemia and Leukemic Stem Cells In Vitro and In Vivo

To target drug-resistant primitive leukemic cells better, scientists designed a CD34/CD3 bi-specific T-cell engager and characterized its anti-leukemia potential in vitro, ex vivo and in vivo.